# Eli Lilly (LLY) — Earnings

LLY · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/lly/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $8.38 |
| EPS estimate | $6.01 |
| EPS surprise | +39.52% |
| Revenue surprise | +11.07% |
| Revenue | $23.0B |
| Revenue estimate | $20.7B |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/c38c4daa-c7f7-4ea4-dc1c-a1657ddfeb08.html) |

Eli Lilly's Q2 2026 results, reported August 5, 2026, brought the highest quarterly revenue in the table. Revenue was $23.0 billion against a $20.7 billion estimate, an 11.07% beat. Earnings per share were $8.38, beating the $6.01 estimate by 39.52%. Compared with Q2 2025, EPS rose 32.8% from $6.31 and revenue rose 47.4% from $15.6 billion. EPS was 2.0% below Q1 2026's $8.55, the peak in the table.

The longer record shows fast but uneven growth. Annual EPS went from $7.94 in 2022 to $6.32 in 2023, then $13.00 in 2024 and $24.21 in 2025. Annual revenue rose from $28.5 billion to $65.2 billion over the same years. Quarterly EPS has swung widely, from a low of $0.10 in Q3 2023. Across the last 20 quarters, Eli Lilly beat EPS estimates 16 times. The largest miss was 26.48%, in Q2 2022, and the most recent was in Q3 2024.

Eli Lilly has reported its third quarter between October 26 and November 2 in recent years, so the next report is likely in late October or early November 2026. First-half 2026 EPS totals $16.93, 75.4% above a year earlier. The key question is whether revenue keeps rising from $23.0 billion.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | $6.01 | $8.38 | 39.52% | $20.7B | $23.0B |
| Q1 2026 | Apr 30, 2026 | $6.97 | $8.55 | 22.71% | $17.8B | $19.8B |
| Q4 2025 | Feb 4, 2026 | $6.91 | $7.54 | 9.10% | $17.9B | $19.3B |
| Q3 2025 | Oct 30, 2025 | $5.69 | $7.02 | 23.33% | $16.1B | $17.6B |
| Q2 2025 | Aug 7, 2025 | $5.60 | $6.31 | 12.70% | $14.7B | $15.6B |
| Q1 2025 | May 1, 2025 | $3.26 | $3.34 | 2.51% | $12.7B | $12.7B |
| Q4 2024 | Feb 6, 2025 | $5.04 | $5.32 | 5.45% | $13.5B | $13.5B |
| Q3 2024 | Oct 30, 2024 | $1.42 | $1.18 | -16.97% | $12.1B | $11.4B |
| Q2 2024 | Aug 8, 2024 | $2.74 | $3.92 | 42.93% | $10.0B | $11.3B |
| Q1 2024 | Apr 30, 2024 | $2.47 | $2.58 | 4.64% | $8.9B | $8.8B |
| Q4 2023 | Feb 6, 2024 | $2.30 | $2.49 | 8.45% | $8.9B | $9.4B |
| Q3 2023 | Nov 2, 2023 | −$0.18 | $0.10 | 155.90% | $9.0B | $9.5B |
| Q2 2023 | Aug 8, 2023 | $1.98 | $2.11 | 6.61% | $7.6B | $8.3B |
| Q1 2023 | Apr 27, 2023 | $1.73 | $1.62 | -6.13% | $6.9B | $7.0B |
| Q4 2022 | Feb 2, 2023 | $1.78 | $2.09 | 17.22% | $7.3B | $7.3B |
| Q3 2022 | Nov 1, 2022 | $1.91 | $1.98 | 3.44% | $6.9B | $6.9B |
| Q2 2022 | Aug 4, 2022 | $1.70 | $1.25 | -26.48% | $6.8B | $6.5B |
| Q1 2022 | Apr 28, 2022 | $2.29 | $2.62 | 14.30% | $7.3B | $7.8B |
| Q4 2021 | Feb 3, 2022 | $2.45 | $2.49 | 1.79% | $7.7B | $8.0B |
| Q3 2021 | Oct 26, 2021 | $1.96 | $1.94 | -1.16% | $6.6B | $6.8B |

## Frequently Asked Questions

### When did Eli Lilly (LLY) last report earnings?

Eli Lilly last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did LLY beat earnings estimates?

Yes. Eli Lilly reported EPS of $8.38 for Q2 2026 against a $6.01 estimate — a 39.52% beat.

### How much revenue did LLY report last quarter?

Eli Lilly reported $23.0B in revenue for Q2 2026, against a consensus estimate of $20.7B.

## Similar Stocks

- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock
- [VKTX](https://www.lighthorse.io/tickers/vktx) — Viking Therapeutics, Inc. - Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [BIIB](https://www.lighthorse.io/tickers/biib) — Biogen Inc. - Common Stock
- [INCY](https://www.lighthorse.io/tickers/incy) — Incyte Corporation - Common Stock
- [NVDA](https://www.lighthorse.io/tickers/nvda) — NVIDIA Corporation - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).